We profiled the whole mutation atlas of the ccRCC patients in the POLD1high and POLD1low groups (Figure 3C), and found it different from the top five genes of mutations in the POLD1low group (VHL (47%), PBRM1 (39%), TTN (16%), BAP1 (8%), MUC16 (7%)); the genes with a higher proportion of mutations in the POLD1high group were VHL (43%), PBRM1 (40%), SETD2 (15%), TTN (15%), and BAP1 (11%) (Supplementary Figure S4C,D). This evidence concerns the gene SETD2 and nonpapillary renal cell carcinoma.